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1. Introduction 
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes 
is a series of editorials which is published on a biannual basis by the Editorial Board of the Medicinal 
Chemistry section of the journal Molecules. In these editorials, we highlight in brief reports (of about 
one hundred words) a number of recently published articles that describe crucial findings, such as 
the discovery of novel drug targets and mechanisms of action or novel classes of drugs, which may 
inspire future medicinal chemistry endeavors devoted to addressing prime unmet medical needs. 
2. Targeting MAO Isoforms by cis/trans Isomers 
Highlighted by Michael Gütschow 
Human monoamine oxidases (hMAO) A and B, two therapeutically relevant isoforms for central 
nervous disorders, share 70% sequence identity and are distinguished by different substrate 
specificities and inhibitor sensitivities. The groups of Stanislav Gobec (Faculty of Pharmacy, 
University of Ljubljana, Slovenia), Mariel Marder (Facultad de Farmacia y Bioquimica, Universidad 
de Buenos Aires, Argentina) and Claudia Binder (Department of Biology and Biotechnology, 
University of Pavia, Italy) have discovered the first example of hMAO-A and hMAO-B inhibitor pairs 
(1-propargyl-4-styrylpiperidines) whose selectivity is conferred by the configurational cis/trans 
isomerism [1]. Thus, the authors provided an impressive example of cis and trans isomers with 
different pharmacological activities resulting from a discrimination between structurally related 
enzyme isoforms. An expanded library of test compounds synthesized, and enzyme inhibition was 
investigated by kinetic analysis, UV/VIS measurements and X-ray crystallography and confirmed ex 
vivo in tissue homogenates as well as in vivo in mice. The results of this study are definitely useful 
for the design of further selective inhibitors of the two MAO isoforms. 
3. A New Lead in the Combat Against the Multi-Drug Resistant Mycobacterium Abscessus 
Highlighted by Jean Jacques Vanden Eynde 
Mycobacterium abscessus is a nontuberculous ubiquitous pathogen responsible for different kinds 
of opportunistic infections, including pulmonary attacks and skin and soft tissues diseases. The 
species is resistant to most antibiotics and disinfectants, and many treatments require the use of an 
association of multiple drugs. In a recent study, de Ruyck et al. [2] focused their attention on the 
design, synthesis, and evaluation of piperidinol-containing molecules (Figure 1) that target the 
flippase activity of the mycolic acid transporter MmpL3. They have demonstrated that such an 
inhibition can result directly in the death of the pathogen. It is noteworthy that it could also be 
exploited in order to create synergetic effects by facilitating penetration of other substances (i.a. β-
lactams) through the wall of the mycobacterium. 
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Figure 1. Representative example (PIPD1) of a piperidinol-containing molecule evaluated by de 
Ruyck et al. [2]. 
4. New InhA Inhibitors Provided by Fragment-Based Drug Design 
Highlighted by Josef Jampilek and CongBao Kang 
Fragment-based drug design (FBDD), despite its youth, has provided marketed drugs and 
others in clinical trials. It has become an effective strategy for designing lead compounds [3]. The 
library used in FBDD contains several thousand fragments and is still growing [4]. FBDD usually 
includes three steps: fragment screening, confirmation and growth. A recent study by Sabbah et al. 
has shown the application of FBDD to the design of original inhibitors of Mycobacterium tuberculosis 
InhA, which is an important target for tuberculosis. Differential scanning fluorimetry was used to 
screen a library of 800 fragments, and 18 hits were identified. NMR and X-ray methods were used to 
confirm the identified hits. The FBDD approach led from 3-trifluoromethylcinnamic acid to potent 
InhA inhibitors based on the N-[3-(aminomethyl)phenyl]-1-benzothiophene-2-sulfonamide scaffold 
with submicromolar IC50 values [5]. Although the real minimum inhibitory/bactericidal 
concentrations, the potential of the compounds to generate resistant/cross-resistant strains, the 
stability, and the ADME properties of the compounds should be investigated, this study 
demonstrated that FBDD is helpful for developing new inhibitors of a well-studied enzyme using a 
routine strategy, while careful and rational chemical design is required. 
5. Combined Modulation of Farnesoid X Receptor and Target Genes: A Promising Therapeutic 
Strategy in Non-Alcoholic Steatohepatitis 
Highlighted by Arduino A. Mangoni 
Novel, highly effective therapeutic strategies are urgently needed for the management of non-
alcoholic steatohepatitis (NASH), an increasing cause of chronic liver failure worldwide [6]. Chianelli 
et al. report the synthesis of a series of non-bile acid farnesoid X receptor (FXR) agonists based on a 
tricyclic dihydrochromenopyrazole core [7]. In particular, compound 1, 4-[(N-benzyl-8-chloro-1-
methyl-1,4-dihydrochromeno[4,3-c]pyrazole-3-carboxamido)methyl]benzoic acid exhibited partial 
FXR agonistic activity in vitro and FXR-dependent gene modulation in vivo. These effects were 
associated with a favorable pharmacokinetic profile in rodents, particularly, high bioavailability, 
moderate volume of distribution and clearance, and short half-life. Furthermore, in an insulin-
deficient murine NASH model, treatment with compound 1 caused a significant dose-dependent 
reduction in parameters of liver steatosis, inflammation and fibrosis. After the successful completion 
of Phase 1 studies in healthy volunteers, compound 1 is currently being investigated in Phase 2 
studies in patients with NASH. Pending the results of such studies, the available evidence suggests 
that the combined modulation of the farnesoid X receptor and target genes might represent a 
promising therapeutic strategy for NASH. 
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6. Cyclodextrins as a Potent Tool for Fighting Multiple Viral Infections 
Highlighted by Paola Fossa and Rafik Karaman 
Viral infections kill millions of people and, especially now, the need for new antivirals is great. 
Unfortunately, all virucidal molecules described to date are strongly cytotoxic, limiting their 
therapeutic application in several patient types or determining severe side effects. Cyclodextrins (CD) 
are naturally occurring glucose derivatives with a rigid cyclic structure, consisting of alpha (1–4)-
linked glucopyranoside units. Recent work by Stellacci and Tapparel [8] showed that the team 
successfully engineered novel modified entities utilizing cyclodextrins. These entities attract viruses 
before breaking them down on contact, thus causing destruction of the virus and combating the 
infection. The novel entities are CDs with a sulfonated alkyl chain (Figure 2), representing a new class 
of non-toxic, broad-spectrum, biocompatible and virucidal drugs. 
 
Identifier CD1 CD2 CD3 
EC50 
(μg/mL) 
28.51 n.a. 11.44 
EC50 
(μg/mL) 
88.89 n.a. 28.13 
Figure 2. Structure of the modified cyclodextrins. 
This new development has the potential to derive effective treatments of herpes simplex, 
hepatitis C, HIV, respiratory syncytial virus, and Zika virus. Undoubtedly, the modified CDs may 
represent a very interesting therapeutic opportunity to be fully investigated. 
7. Probing Amyloid Oligomers is Key to Solving the Neurodegeneration Puzzle 
Highlighted by Andrea Trabocchi and Peter J. H. Scott 
Many neurodegenerative disorders (NDs) are characterized by misfolding, aggregation, and 
accumulation of amyloid proteins. Accumulating amyloid deposits cause loss of cellular function and 
synaptic connections, brain damage and eventual death. Reflecting this, there has been significant 
interest in using amyloid deposits as an imaging biomarker to improve our understanding of 
mechanisms underpinning NDs [9]. Thioflavin T (ThT) is a fluorescent dye that has been used 
extensively to study amyloid fibril formation and was also the inspiration for development of the 
prototypical amyloid PET radiotracer [11C]Pittsburgh Compound B. 
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However, recent studies suggest that the small soluble oligomers arising during fibril formation 
are actually the toxic and pathogenic form of the misfolded protein, rather than the deposits 
themselves [10]. Unfortunately, poor photophysical and binding properties of ThT limit its use to 
study oligomers, and next-generation probes enabling the detection of amyloid oligomers are 
urgently needed. To address this, Needham et al. have developed Thioflavin X (ThX, Figure 3) [11]. 
ThX displayed 5- and 7-fold increases in brightness and affinity, respectively, resulting in enhanced 
detection of structural differences in early oligomeric species not observed via traditional ThT 
imaging. 
 
Figure 3. Pathway of amyloid fibril formation starting from monomeric proteins and the common 
cross-β sheet motif of amyloid fibrils to which benzothiazole salts bind. The binding of ThX to the 
fibrils restricts the rotation around the C—C bond resulting in a fluorescence turn-on response. 
Reprinted from Ref [11]—published by the Royal Society of Chemistry. 
8. Tyrosyl-DNA Phosphodiesterase 2 as a Novel Target to Enhance the Efficacy of 
Topoisomerase II Poisons 
Highlighted by Jóhannes Reynisson 
The mechanism of action of many anticancer drugs in clinical use is based on damaging DNA 
due to the rapid growth of tumor cells. These include topoisomerase II (TOP2) poisons such as 
etoposide and mitoxantrone, which trap the TOP2-DNA cleavage complexes, resulting in apoptosis 
of the cancer cells. However, the repair enzyme Tyrosyl-DNA phosphodiesterase 2 (TDP2) can undo 
the trapped TOP2-DNA complexes, thus counteracting the effect of the TOP2 poisons, allowing the 
cancer cells to survive and develop resistance to chemotherapy. Recently, a report on an improved 
TDP2 inhibitor ZW-1288 (Figure 4) with low nanomolar activity was released [12]. This ligand is a 
deazaflavin derivative and potentiates etoposide and mitoxantrone in prostate, leukemia and 
lymphoma cancer cells, whilst expressing weak cytotoxicity. This demonstrates that inhibiting TDP2 
with a drug-like small molecule is possible making this enzyme a very promising therapeutic target 
[12]. 
N
N NO
O
CN
ZW-1288
OH  
Figure 4. The molecular structure of ZW-1288. 
9. Proteostasis Network: A New Paradigm for Drug Discovery? 
Highlighted by Simona Rapposelli 
Oxidative stress is frequently addressed as the main cause of aging. However, different 
processes have been identified that contribute significantly to the onset of neurodegenerative diseases 
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(NDDs), such as the progressive inefficiency of the proteostasis network [13]. Indeed, among the 
dysfunctional mechanisms occurring with aging, two protein degradation systems, the ubiquitin–
proteasome system (UPP) and the autophagy–lysosome pathway (ALP) are being impaired. 
Therefore, the development of innovative and multivalent therapies aimed at sustaining proteome 
balance is a challenging strategy to identify drug treatments for chronic and disabling diseases or for 
aging prevention. To date, natural compounds have been recognized as multifunctional molecules 
capable of influencing the stability of the proteome [14], thus representing a valid starting point to 
design and synthesize new modulators of the proteostasis network. 
10. The Fascinating Perspective of Material Science: Precise Embolization in Tumor Vessels 
Through Peptide-Based Nanoparticles 
Highlighted by Stefania Galdiero 
The development of cancer therapeutic strategies based on angiogenesis attracts great interest 
in biomedicine and biotechnology research and could lead to novel materials having great potential 
in clinics. Zhang et al. [15] prepared an embolus inside a tumor’s blood vessels to block them, through 
mimicking laminin fibrillogenesis, specifically and highly efficiently. This strategy resulted in the 
blockage of the tumor vessels and in a higher inhibition of tumors. In particular, the development of 
dual-responsive peptide-based nanoparticles made of a fibrillation sequence, a pH-responsive 
sequence and a targeting sequence is reported. The peptide nanoformulations are delivered to blood 
vessels in the tumors where the microenvironment enables formation of the fibrous network, which 
captures the red blood cells forming occlusions specifically in the tumor blood vessels and inhibiting 
the growth of the tumor. A biomimetic and promising approach to attack tumor cells and cause tumor 
cell death was developed, which suggests that material science may be exploited for in-situ 
construction of therapeutic agents for disease treatment. 
11. Promising Anti-Leishmania Compounds in the Telluride Sulfonamide Series 
Highlighted by Jean-Yves Winum 
Leishmaniasis is a neglected parasitic infection that causes skin or visceral lesions and can be 
fatal if left untreated. Due to the emergence of resistant parasites, there is an urgent need to find new 
targets and to develop more effective and less toxic drugs. Leishmania donovani chagasi β-carbonic 
anhydrase (LdcCA) is playing a key role in the growth and virulence of the parasite; thus, specific 
LdcCA inhibitors could help fighting this disease more effectively. [16] Angeli and colleagues have 
reported the discovery of substituted aryl-benzyl telluride compounds, bearing a sulfonamide 
moiety. These compounds displayed nanomolar inhibitory activity against LdcCA. One of the best 
inhibitors showed high antileishmanial activity, displaying (i) a selectivity index over 300-fold higher 
for the L. infantum axenic amastigotes over THP1 cells and (ii) a selectivity up to 50 times higher than 
edelfosine against infected macrophages. In-vitro and in-vivo toxicity experiments have highlighted 
the innocuity of this compound. [17] This study provides new directions for the design and 
subsequent development of drug candidates targeting the carbonic anhydrase of Leishmania or more 
generally of other protozoan parasites. 
12. New Insight in Fak Inhibitors 
Highlighted by Chiara Brullo 
Fak is a cytoplasmic protein tyrosine kinase overexpressed and activated in different solid 
cancers. It has been proposed as a potential target in cancer therapy, particularly in a metastatic 
phase. Zhao et al., miming the bioactive conformation of the well-known diaminopyrimidine motif 
and using a cyclization strategy, synthesized a large series of 7H-pyrrolo[2,3-d]pyrimidines as Fak 
inhibitors. Very recently, they obtained new 2,7-disubstituted-thieno[3,2-d]pyrimidine compounds 
by isosteric replacement of a pyrrole nucleus by a thiophene one [18], the most relevant being 1 
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(Figure 5), which showed an IC50 value of 28.2 nM in an enzymatic assay and displayed stronger 
potency than the reference compound TAE-226 in different biological assays. 
As found in a docking study, compound 1 is anchored to the hinge region by double-dentate 
hydrogen bonds of pyrimidine nitrogen and aniline NH to the hinge region, whereas the o-methoxyl 
group is involved in the hydrogen bond with Asp564 of the DFG motif (Asp-Phe-Gly). Furthermore, 
the water-soluble “tail” of the piperidine moiety interacts with Cys427, confirming its important role 
in enzymatic inhibition. For all these reasons, this compound could be a promising lead for Fak-
targeted anticancer drug discovery. 
 
Figure 5. Chemical structure of the lead compound in the work by Zhao et al. [18]. 
13. Tackling Coronas with EIDD-2801 Pills? 
Highlighted by Katalin Prokai-Tatrai 
The small molecule β-d-N4-hydroxycytidine (NHC) is a ribonucleoside analogue that inhibits 
viral RNA genome replication and is effective against a variety of viruses, including the cause of the 
current pandemic: coronavirus disease 2019 (COVID-19). NHC’s 5′-isopropyl ester prodrug, 
identified as EIDD-2801, was designed to improve pharmacokinetics and oral bioavailability in 
humans and nonhuman primates. It has recently been reported [19] that, when used as a 
prophylactic, oral administration of EIDD-2801 resulted in a significant viral load reduction and 
improved pulmonary function in mice infected with severe acute respiratory syndrome CoV (SARS-
CoV) or Middle East respiratory syndrome CoV (MERS-CoV). Additionally, the weight loss of the 
experimental animals also markedly decreased. When given as a treatment within 12 or 24 h post-
infection, the degree of lung damage could also be reduced. This window of therapeutic opportunity 
is expected to be significantly longer in humans. Overall, EIDD-2801 pills hold promise for not only 
the treatment of COVID-19 patients today but also against new CoVs that may emerge in the future. 
14. Developing Efficient Mutant GTPase KRASG12C Inhibitors: Are We Ready for Mutant KRAS 
Yet? 
Highlighted by Arun K. Sharma 
KRAS, a key regulator of signaling pathways that cause cells to proliferate and differentiate, is 
a frequently mutated oncogene in human tumors, and G12C is the most common KRAS mutation in 
lung adenocarcinoma. Many efforts to develop KRASG12C-specific inhibitors are currently 
underway—AMG510 (Amgen) and MRTX849 (Mirati/Array) are in clinical trials. Kettle et al. [20] 
further optimized covalent allosteric inhibitors of the mutant GTPase KRASG12C through 
conformational locking of a piperazine−quinazoline motif and linker modification and introducing a 
methyl group to the piperazine, leading to identification of a potent KRASG12C inhibitor with high 
selectivity, improved drug-like properties and excellent in-vivo efficacy. Although more studies 
would be required to establish the promise of this compound, this is a significant step forward in 
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designing KRASG12C inhibitors. However, a recent report [21] suggests that resistance is inevitable for 
KRASG12C inhibitors since the cancer cells develop a heterogeneous response to the inhibitors and 
bypass inhibition by producing new active KRASG12C that does not bind the inhibitor, indicating that 
the challenge to develop efficient inhibitors and achieve complete responses in the clinic continues. 
15. A Senolytic PROTAC Exploits the Restricted Expression Profile of CRBN to Lose Toxicity 
Associated with Its Parent Inhibitor 
Highlighted by Matthieu Schapira 
PROTACs are heterobifunctional molecules that recruit an E3 ligase to a target protein, leading 
to proteasomal degradation of the target. This novel modality is expected to extend the boundaries 
of the druggable genome [22]. He et al. have now established an additional benefit of PROTACs: the 
authors exploit the expression profile of the recruited E3 ligase to inhibit the target in tissues where 
it is pathogenic, while sparing it in tissues where it is beneficial [23]. 
Senolytics are compounds that selectively kill senescent cells implicated in age-related diseases 
such as osteoarthritis or cardiovascular and neurodegenerative diseases. ABT263, a protein 
interaction inhibitor that targets the anti-apoptotic proteins Bcl-xl and Bcl-2, is one of the most potent 
senolytics, but has unacceptable on-target toxicity, as Bcl-xl inhibition induces platelet apoptosis, 
resulting in severe thrombocytopenia. In an elegant work, He et al. have developed a PROTAC 
derived from ABT263 that recruits the E3 ligase CRBN to degrade Bcl-xl. Because CRBN is expressed 
in senescent cells but not in platelets, the PROTAC conserved the senolytic activity of ABT263 but 
lost its toxicity. 
16. Possibility to Use Interleukin Itself for Treatment—IL-37 as an Example 
Highlighted by Yasu-Taka Azuma 
Up to now, more than 40 kinds of interleukins have been reported, and most of them induce 
inflammation. Therefore, until now, most of the therapeutic applications of interleukins have focused 
on blocking the action of interleukins using neutralizing antibodies. However, some interleukins, 
typically IL-10, have been found to have anti-inflammatory effects. Ballak et al. have reported that 
IL-37, which is an anti-inflammatory interleukin itself, has therapeutic potential [24]. They 
investigated the effectiveness of IL-37 treatment for improvement of physiological function in the 
elderly. Recombinant IL-37 treatment to old mice increased vascular endothelial function and 
endurance exercise capacity and improved whole-body insulin sensitivity and glucose tolerance. In 
addition, IL-37 has also been reported to show anti-inflammatory effects in patients with 
arteriosclerosis [25]. This interleukin therapy has further expanded the options for treating various 
diseases. 
17. RNA-Based Nanoconstructs for Targeted Delivery of Paclitaxel to Breast Cancer: The Road to 
Drug Efficacy and Safety 
Highlighted by Laura Cerchia 
Targeted delivery of chemotherapy enhances the anticancer activity of the drug and limits side 
effects on healthy organs by increasing its concentration at the tumor site while dispensing lower 
absolute doses of the drug. Consequently, the development of novel cancer-targeted drug delivery 
systems represents one of the hottest areas of modern cancer research. Recently, Guo et al. [26] 
constructed a smart RNA-based multifunctional nanovector for targeted delivery of paclitaxel, whose 
use in the clinic is limited by scarce bioavailability and severe toxicity, to triple-negative breast cancer, 
by using aptamers for guaranteeing tumor targeting. Specifically, a ″X″-shaped RNA four-way 
junction nanostructure with ultra-thermodynamic stability was assembled with the extraordinary 
loading capability of twenty-four paclitaxel molecules as the prodrug. The intravenous injection of 
the construct, equipped with a previously validated and high efficacious anti-EGFR aptamer, in mice 
bearing orthotopic tumors greatly inhibited breast cancer growth. Further, nanoconstructs exhibited 
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low/undetectable toxicity or immune responses in mice. Improving the transport of the drug to the 
tumor, by specific drug delivery platforms, will open up the possibility of accessing lower-cost and 
highly effective therapies. 
18. New Insights into Mechanisms for Allosterically Modulating the Kappa Opioid Receptor 
with Nanobodies 
Highlighted by Mariana Spetea 
G-protein-coupled receptors (GPCRs) represent the most-targeted class of druggable proteins in 
the human genome [27]. The kappa opioid receptor (KOR) has emerged as an important therapeutic 
target for the treatment of pain and neuropsychiatric conditions. As a GPCR, KOR rapidly 
interconverts between multiple states, though the ability to visualize them is limited by a relative lack 
of suitable tools. Nanobodies (Nbs) provide a powerful platform to stabilize distinct receptor 
conformations. Che et al. [28] have demonstrated, via X-ray crystallography, a nanobody-targeted 
allosteric binding site of KOR, by which Nb6 stabilizes a ligand-dependent inactive state and Nb39 
stabilizes an active-like state. They have shown how these two state-dependent nanobodies can 
provide real-time reporting of ligand stabilized states in cells in situ. Analysis of the KOR–Nb6 
complex revealed a unique nanobody binding interface by which Nb6 negatively allosterically 
modulates KOR. The observation that this site can be transferred to other GPCRs to provide an 
engineered and functional allosteric site was also remarkable. Furthermore, given that Nb6 and Nb39 
interact with distinct states of KOR, they can be used as biosensors to detect ligand-stabilized states 
in real time in living cells. 
19. Is the Role of LMW Heparin in COVID-19 Infection Really Only Antithrombotic or Not? 
Highlighted by Giangiacomo Torri 
My answer to the question is no. It is well established that polyanionic molecules exhibit 
antiviral activities. Concerning heparin, the most relevant polyanionic macromolecule expressed by 
mammalian organisms, in the literature there are more than 3500 articles stating its antiviral activities 
with respect to different kinds of viruses. Among the 62 articles concerning SARS-CoV-2 and heparin, 
a basic research study by researchers experienced in glycosaminoglycans and proteins has 
demonstrated that a physical–chemical interaction between heparin and the viral protein occurs [29]. 
The current pandemic took us by surprise, and we found ourselves mostly unprepared to 
manage it in terms of experience and availability of adequate drugs, despite numerous studies on 
non-anticoagulant heparin derivative candidates. It is necessary to pursue a larger interchange 
between basic research, drug development and clinical knowledge. The goal is to minimize the 
dichotomy between clinical world and laboratory research. 
20. Identification of Small Molecules Targeting Zika Virus NS2B-NS3 Protease via Fragment-
Based Drug Discovery (FBDD) Approach 
Highlighted by Simona Collina 
In their recent publication, Quek et al. [30] have reported the successful application of a 
fragment-based drug discovery (FBDD) approach to identify small molecules targeting Zika virus 
(ZIKV) protease. ZIKV is a mosquito-borne flavivirus, which recently emerged as a global health 
threat. The viral NS2B-NS3 protease has an essential role in the maturation of viral proteins and 
represents an attractive therapeutic target for fighting ZIKV. The major drawback for development 
of NS2B-NS3 inhibitors is the negatively charged binding site. With the final aim to identify molecules 
with high affinity to the pocket and with drug-like properties, the authors adopted a FBDD approach. 
Employing a primary thermal shift assay, a fragment library of 1685 compounds was screened against 
the Zika protease, and twenty-two fragments were selected. After co-crystallization experiments, the 
X-ray structures of two complexes were successfully solved, showing that both compounds interact 
with the same site. These two hits were further characterized by STD NMR studies confirming their 
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molecular interactions with the target. These fragments can be used as starting compounds for further 
growing into more potent inhibitors, thus paving the way for the discovery of novel effective ZIKV 
protease inhibitors. 
21. Synthesis and Chemical Profile of New HIV-1 Capsid Targeting Peptidomimetic Analogous 
of PF74 
Highlighted by Athina Geronikaki 
The infection and dismantling of T cells engineered by the human immunodeficiency virus 
(HIV) induce human acute immunodeficiency syndrome (AIDS). The capsid protein (CA) 
involved in HIV-1 possesses a central role in various steps of the cycle of virus replication: 
in convening the core of functional capsid, regulating the kinetics of DNA entry and viral 
core uncoating with multiple host–factor interactions. 
Among all known small molecule chemotypes that target CA, the peptidomimetic PF74 has 
drawn particular interest since it exhibits a binding ability to the corresponding pocket. 
Wang et al. [31] have provided a thorough chemical optimization of PF74 by synthesizing and 
evaluating a broad amount of PF74 analog (Figure 6). Antiviral tests and CA hexamer stability 
accomplished on these analogs revealed occasional key pharmacophore aspects, including a phenyl 
moiety, a halogen para-substitution and a tiny alkyl group at the nitrogen in the aniline region, and 
the tolerance of carbon-3 and NH belonging to the indole skeleton for adjustment. 
 
Figure 6. General structure of synthesized compounds. 
22. Let Cancer Cells Trip Themselves Up 
Highlighted by Alfonso T. Garcia-Sosa 
Many drug design efforts towards cancer therapy have concentrated on stopping the cellular 
processes of diseased cells. A new approach by Schulze et al. [32] overrides the spindle assembly 
checkpoint with small molecule inhibitors of MPS1 kinase, so that cancerous cells are allowed to 
progress to cell division with errors and mutations in their DNA in a so-called mitotic catastrophe. 
This has the effect of killing the cells at a later stage. Two separate chemical series were optimized 
with X-ray studies leading to two highly potent clinical candidates with favorable in-vivo PK 
properties: triazolopyridine BAY 1161909 and imidazopyridazine BAY 1217389. These ATP-
competitive inhibitors make use of differently shaped binding pockets of MPS1 as well as different 
interactions with the protein. They are also synergistic in combination with the chemotherapy drug 
paclitaxel, which acts by interference with the normal function of microtubules during cell division. 
These compounds are the first MPS1 inhibitors to enter Phase I clinical trials, doing so with a novel 
mechanism of action. 
23. Studies on SARSCoV-2 Spike Glycoprotein Open Doors for Covid-19 Drug Discovery 
Highlighted by M. Helena Vasconcelos and Maria Emília Sousa 
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Three highly pathogenic zoonotic coronaviruses emerged recently: SARS-CoV in 2003, MERS-
CoV in 2012, and SARS-CoV-2 in 2019. Coronavirus entry into host cells is mediated by the 
transmembrane spike (S) glycoprotein. In this study, Walls et al. [33] demonstrated that SARS-CoV-
2 S uses ACE2 to enter cells. In addition, cryo-electron microscopy structures of the SARS-CoV-2 S 
glycoprotein revealed the presence of multiple conformational states of the SARS-CoV-2 S 
ectodomain trimer, providing important information for the discovery of vaccines and drugs to 
inhibit viral entry into cells. Finally, these authors observed a sequence and conformational 
conservation of the S protein fusion peptide regions between two coronaviruses (SARS-CoV-2 and 
SARS-CoV), putting forward the idea that infection by one of these two viruses could cause 
production of antibodies which might cross-react and neutralize both viruses as well as other related 
coronaviruses. Indeed, their results indicated that SARS-CoV S murine polyclonal antibodies 
potently inhibited SARS-CoV-2 S-mediated entry into cells. 
24. With or Without ssDNA Genome, Pf4 Filamentous Phage Promotes the Stability of P. 
Aeruginosa Biofilm Formation and Consequently Increases Protection Against Antibiotics 
Highlighted by Ivan Kosalec 
Opposite to the well-known predation effects of bacteriophages on bacteria, filamentous phages 
express an interesting evolution-driven symbiotic relationship. Filamentous phages contain an 
ssDNA genome and very long and thin helically packed capsids. They do not harm the bacterial host, 
and, after egressing from the host, these phages symbiotically help bacteria to survive and to form 
more protected biofilms, especially during Pseudomonas aeruginosa infection [34,35]. The recent work 
of Tarafder et al. [36] has provided deeper insights into Pf4 filamentous phage and P. aeruginosa 
biofilm interactions, showing that Pf4 phages with ssDNA and capsid shell form protecting liquid 
shields around P. aeruginosa cells in biofilms. Removing the genome, Taragder et al. [36] found that 
phages with empty protein-structure capsid shells called “ghosts” formed liquid crystals around 
bacterial cells still protecting bacteria from antibiotic treatment. These observations have a great 
impact on bacteriophage–P. aeruginosa cell interactions in biofilms and reveal a more complex 
influence of Pf4 phages. Our strategy to modulate these effects on biofilms caused by P. aeruginosa 
must change as well. 
25. An NMR Drug Screening Approach in Human Cells as a New Tool for Drug Potency Early 
Assessment 
Highlighted by Tiziano Tuccinardi and Iola F. Duarte 
A classical drug development workflow usually starts by screening the activity of multiple 
ligands against the selected target. Once a hit is identified, its chemical structure is used as a starting 
point for chemical modifications to improve potency and selectivity. However, promising candidates 
showing good performance in vitro often lack in-vivo activity, due to low membrane permeability or 
poor intracellular binding selectivity. Banci et al. reported an innovative experimental protocol to 
screen ligands in living human cells by “intracellular protein-observed” NMR spectroscopy, without 
requiring enzymatic activity measurements or other cellular assays. The method proposed is based 
on the observation and spectral deconvolution of 1H signals arising from free and ligand-bound 
fractions of the target macromolecule. Signal areas are used to build quantitative dose and time-
dependent ligand binding curves, from which kinetic and thermodynamic parameters linked to cell 
membrane permeability and binding selectivity are retrieved [37]. Such an approach, applied in this 
work to carbonic anhydrase but extendable to other NMR-observable intracellular targets, represents 
a useful means to predict drug potency at an early stage of the development process. 
26. Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance 
Highlighted by Jorge A. R. Salvador 
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Proteasome inhibitors (PIs), particularly bortezomib, have significantly improved the overall 
survival and quality of life of multiple myeloma (MM) patients. However, cancer resistance and 
relapse remain major difficulties in expanding the clinical utility of PI drugs. 
Hao Fang et al. [38] have designed and synthesized a novel series of peptide boronate derivatives 
as dual inhibitors targeting both histone deacetylases (HDACs) and proteasomes to address the 
resistance of bortezomib. The most potent inhibitors, ZY-2 (Figure 7) and ZY-13, showed excellent 
inhibition against proteasome and good selectivity against HDACs. 
Specifically, ZY-2 also exhibited good antiproliferative activities on the MM cell lines RPMI-
8226, U266, and KM3 (IC50 values of 6.66, 4.31, and 10.1 nM, respectively). In addition, ZY-2 showed 
more potent antiproliferative activities against the bortezomib-resistant MM cell line KM3/BTZ 
compared with bortezomib (IC50 values of 8.98 vs. 226 nM, p < 0.01). Moreover, ZY-2 also exhibited 
excellent potency in cell apoptosis induction and cell cycle arrest and decreased the levels of Sp1 and 
HDAC1 at low concentrations in the bortezomib-resistant MM cells. 
 
Figure 7. Chemical structure of ZY-2. 
27. BRAF-V600E Degraders: A New Weapon Against Melanoma 
Highlighted by Massimo Bertinaria and Maurizio Pellecchia 
The activating mutation V600E in the kinase BRAF is a major driver in several human cancers. 
BRAF-V600E produces a constitutively active kinase, which signals the expression of proliferation 
and survival genes in cancer cells [39]. BRAF-V600E inhibitors, such as vemurafenib, dabrafenib and 
encorafenib, are currently clinically approved for the treatment of BRAF-V600E-driven melanoma. 
One major drawback of these inhibitors, however, is represented by their paradoxical induced 
activation of wt-BRAF and concomitant activation of ERK signaling. Hence, in a potentially 
transformative new approach, Wang et al. have developed proteolysis-targeting chimeras 
(PROTACs) able to promote a selective proteasome-mediated degradation of mutant BRAF-V600E 
[40]. Two agents were obtained by linking vemurafenib to thalidomide using a short spacer, and by 
linking BI882370 (a newer and more selective BRAF-V600E inhibitor) to pomalidomide using a PEG-
based spacer. The new agents are able to induce degradation of BRAF-V600E at nanomolar 
concentrations and inhibit the growth and viability of A375 melanoma cells. Most importantly, the 
agents do not promote degradation of wild-type BRAF, hence sparing non-neoplastic human cells. 
28. Target-Guided Synthesis of Noncanonical DNA-Binding Transcriptional Modulators 
Highlighted by Jussara Amato 
G-quadruplex and i-motif are four-stranded noncanonical nucleic acid structural arrangements. 
Recent evidence suggests that these DNA structures exist in living cells and are involved in several 
cancer-related processes, like the transcriptional regulation of proto-oncogenes, thus representing an 
attractive target for anticancer drug discovery. Considering the dynamic nature of DNA structures, 
the development of small molecules that can bind to them with high affinity and selectivity has 
always been challenging and time consuming. Dash et al. have reported an innovative example of a 
target-guided synthetic approach, using DNA-immobilized magnetic nanotemplates and an array of 
azide and alkyne fragments, in which the active site of the biological target controls the assembly of 
the best binding fragments [41]. The in-situ-generated lead compounds can be easily isolated by 
simple magnetic decantation, and DNA templates can be recovered and recycled. The identified 
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small molecules effectively showed high affinity and specificity for the target, as well as the ability to 
modulate gene expression. This approach might pave the way to in-situ development of 
transcriptional modulators for therapeutic interventions. 
29. The Crystal Structure of the SARS-CoV-2 Main Protease: New Hopes to Fight a Threatening 
Disease 
Highlighted by Giulio Rastelli 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the new virus responsible 
for the COVID-19 outbreak, is posing a real threat to global health. Jin et al. [42] have described the 
crystal structure of the main protease (Mpro) of SARS-CoV-2 (Figure 8), an essential enzyme of the 
viral life cycle. The authors firstly developed a fluorescence resonance energy transfer assay 
compatible with high-throughput screening, then solved the crystal structure of SARS-CoV-2 Mpro 
in complex with the Michael acceptor inhibitor N3 at 2.1 Å and 1.7 Å resolutions (PDB codes 6LU7 
and 7BQY, respectively). The ligand binds in the substrate cleft by adopting an extended 
conformation (Figure 8); it is covalently bound to catalytic cysteine and establishes several hydrogen 
bonds and hydrophobic contacts. Remarkably, high-throughput screening of a library of about 10,000 
compounds identified six ligands (disulfiram, carmofur, ebselen, shikonin, tideglusib and PX-12) able 
to inhibit the SARS-CoV-2 protease with micromolar IC50, with ebselen and N3 also showing antiviral 
activity. 
Without doubt, the availability of this crystal structure will greatly support the rational 
identification of drug leads and/or repurposed drugs for the treatment of COVID-19, for which 
effective therapeutics are still lacking. 
 
Figure 8. Crystal structure of the SARS-CoV-2 main protease in complex with ligand N3 (PDB code 
7BQY). 
30. Stalobacin I: The Newest Member of the Remarkable Family of Peptide-Based Antibiotics 
Highlighted by Paula A. C. Gomes 
Resistance to antibiotics currently available in clinics is reaching alarming levels, and can affect 
anyone, of any age, gender or socio-economic status, in any region of the world. Of particular concern 
are the so-called ESKAPE pathogens, multi-drug resistant (MDR) strains of Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter bacteria that are major players in nosocomial infections. When current antibiotics fail to 
mitigate severe and life-threatening infections, “last-resort” options come into play, including use of 
the well-known natural lipocyclopeptides daptomycin and colistin, or the more recent synthetic 
glycopeptide telavancin [43]. This prominent role of peptide-based antibiotics in the battle against 
MDR infections has been consolidated over recent years by the discovery of other natural peptides 
with non-canonical structures, like teixobactin [44] or lungdunin [45]. Stalobacin I, a lipopeptide now 
identified by Matsui et al., comes to enrich the portfolio of peptide-based antibiotics with potent 
action against MDR Gram-positive bacteria [46]. Hopefully, similar success will soon emerge 
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regarding discovery of as-yet-elusive alternatives to polymyxins or colistin as peptide-based 
antibiotics to fight MDR Gram-negative bacteria. 
31. Are We Now One Step Closer to the Discovery of new Antibiotics or Overcoming Their 
Resistance with Artificial Intelligence? 
Highlighted by Rita C. Guedes and Jean-Marc Sabatier 
Antibiotic-resistant bacteria have risen sharply and are a major challenge in drug discovery. To 
address this challenge, Collins et al. [47] have applied a deep learning approach based on neural 
network training to identify new chemotypes with putative antibacterial activity. Their combined 
approach to identify potential lead compounds consisted of the training of a deep neural network 
model to predict growth inhibition of E. coli (2335 molecules), which was then applied to the screen 
of multiple chemical libraries (>107 million molecules). Selected compounds (the best ranked as 
structurally “unique” compared with other antibiotics and devoid of apparent toxicity) were then 
tested against bacterial growth. Among other potential compounds, the c-Jun N-terminal kinase 
inhibitor SU3327 (halicin) was identified as a potent E. coli growth inhibitor. This work proves the 
importance of the use of machine learning in our drug discovery pipelines to expand conventional 
chemical space. 
32. Design and Synthesis of Oral Bioavailable Chromone Derivatives as Novel Selective BRD4 
Inhibitors 
Highlighted by Ana Estévez-Braun 
BET family proteins, especially BRD4, represent a promising epigenetic target for human 
diseases, such as cancers, inflammations, CNS disorders, heart failure, and HIV infection. A series of 
compounds based on the chromone core were designed and obtained through a scaffold hopping 
approach. Two of them, ZL0513 and ZL0516 (Figure 9), displayed nanomolar binding affinity (IC50 
67–84 nM) with BRD4 BD1 [48]. Their binding modes were validated by the cocrystal structure of 
ZL0516 in complex with human BRD4 BD1. These compounds also showed significant in-vivo 
efficacy in a murine model of TLR3-induced acute airway inflammation. Finally, pharmacokinetic 
studies revealed that both compounds are orally available, indicating their potential as therapeutic 
agents in inflammatory diseases. 
 
Figure 9. Structures of ZL0513 and ZL0516. 
33. Aptamers as a Therapeutic Tool Against Prion Diseases 
Highlighted by Bruno Pagano 
Prion diseases, also known as transmissible spongiform encephalopathies, are fatal 
neurodegenerative disorders affecting humans and animals. An innovative and promising 
therapeutic approach is based on the use of nucleic acid aptamers to block the hallmark event in the 
prion diseases, i.e., the conversion of prion protein into an abnormal form. Starting from a previously 
identified RNA aptamer, Mashima et al. have rationally developed a new aptamer that exhibited very 
high anti-prion activity [49]. Rationalization of the high anti-prion activity was also provided on the 
basis of RNA structure determination. The achievement of an IC50 value of 100 nM represents a 
substantial advance that has opened the realistic possibility of applying these nucleic acid molecules 
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for therapeutic use. The development of drugs against prion diseases is long overdue. These results 
may pave the way to the development of new, powerful tools against diseases lacking effective 
therapy. 
34. A Newly Designed γ–Lactam-Siderophore Conjugate Shows Significant Antibiotic Activity 
Against Multidrug-Resistant Gram-Negative Bacteria 
Highlighted by Stefano Mangani 
The concept of using the siderophore importers present in Gram-negative bacteria to facilitate 
the intake of antibiotics into the periplasmic space [50] has been applied to the development of a new 
compound endowed with interesting activity against multidrug-resistant (MDR) bacteria. Goldberg 
et al. [51] have reported the design, synthesis, structural characterization and antimicrobial activity 
of a novel pyrazolidinone antibiotic containing a dihydroxyphthalimide siderophore mimetic. The 
compound, dubbed YU253434, contains the 2-(2-aminothiazol-4-yl)-2-(2-carboxypropan-2-
yloxyimino)acetamido moiety of ceftazidime linked to the pyrazolidinone nucleus, which in turn 
bears a dihydroxyphtalimide acting as a siderophore mimic (Figure 10). YU253434 acts a covalent 
inhibitor of PBPs (Penicillin Binding Proteins) by binding to the catalytic serine residue as shown by 
the X-ray crystal structure of its complex with PBP3. 
YU253434 is stable with respect to β-lactamases of all classes. Its MICs against clinical isolates of 
relevant MDR bacteria compare favorably with those of β-lactam antibiotics used in clinics. The 
structure of the YU253434 bound to PBP3 provides hints for further optimization of this promising 
compound. 
 
Figure 10. Structure of YU253434. 
35. Tackling SARS-CoV-2: Key Hints for Structure-Based Design of Broad-Spectrum Inhibitors 
of 3CL Protease 
Highlighted by Rino Ragno, George Kokotos, Margherita Brindisi and Florenci V. González 
The COVID-19 pandemic caused by SARS-CoV-2 has generated an unprecedented health 
emergency worldwide. The development of broad-spectrum antivirals useful for future outbreaks of 
pathogenic coronaviruses is of absolute priority. Proteolytic enzymes, essential for producing mature 
virions, represent attractive targets for drug development. One of them is the SARS-CoV-2 
chymotrypsin-like protease (3CLpro), a protease utilizing a Cys–His catalytic dyad for its hydrolytic 
activity. In their quest for novel broad-spectrum 3CLpro inhibitors (Figure 11), Hilgenfeld et al. 
identified compound 1, featuring an α-ketoamide warhead [52]. Based on 1, structure modification 
led to new compounds with an extended activity spectrum against coronaviruses, while improving 
the drug-like profile [53]. In order to enhance metabolic stability and decrease plasma protein 
binding, the P3-P2 amide was embedded into a pyridone ring, and the terminal cinnamoyl portion 
was replaced by a tert-butoxycarbonyl group. The X-ray structures of the unliganded SARS-CoV-2 
3CLpro and its complex with an α-ketoamide inhibitor were solved and enabled structure-based drug 
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design. Compound 2 effectively inhibited the main coronaviruses 3CLpro (SARS-CoV-2, SARS-CoV 
and MERS-CoV) with an average IC50 of 0.79 µM and exhibited promising antiviral potency in cell-
based assays, with associated improved half-life and favorable lung tropism. 
 
Figure 11. Structure of α-ketoamide-based broad-spectrum 3CLpro inhibitors 1 and 2. 
36. Drug Discovery and Central Nervous System Diseases: Neuroinflammation as a Step 
Forward 
Highlighted by Fernanda Borges 
Central nervous system (CNS) diseases are a large group of neurological disorders with 
heterogeneous clinical and pathological expressions. The intricate network of regulatory mechanisms 
remains largely elusive, and, to date, no specific factor has been identified as a direct cause. 
Furthermore, the existing drugs in therapy are only palliative and fail to modify disease progression. 
Identifying and validating novel and druggable CNS targets remains a hot topic in drug 
discovery, in particular those involved in neuroinflammation. Interestingly, the prostanoid EP2 
receptor has been associated with neuroinflammation and neurodegeneration in CNS diseases. In 
this context, the work of Thota Ganesh’s research team reports the discovery of new EP2 antagonists, 
obtained after a lead optimization process. This work describes the improvement of selectivity and 
drug-like properties of the brain-permeating lead TG6-10-1. The optimized antagonist, 2-[(4,6-
dimethylpyridin-2-yl)amino]-N-[2-(2-methyl-1H-indol-3-yl)ethyl]pyrimidine-5-carboxamide 
hydrochloride (TG11-77·HCl), has a higher selectivity index, suitable brain permeability and excellent 
water solubility [54]. 
37. Evaluation of Nonvaccination Preventive Mechanisms to Fight Antibiotic Resistence: 
Evidence from Enteropathogenic E. coli Infection 
Highlighted by Mariarosaria Miloso 
Antibiotic resistance is a crucial problem for human health, and it is fundamental to explore 
alternative therapeutic options to treat bacterial infections. Qiu et al., by in-vitro and in-vivo 
experiments, demonstrated the effectiveness of a specific reactive peptide to block enteropathogenic 
E. coli (EPEC) infection [55]. EPEC infection starts with the attachement of a bacterium to the surface 
of an intestinal cell in order to inject Tir protein into the cytoplasm. Tir interacts with Nck adaptor, 
which, in turn, allows the interaction of Tir with the Arp2/3 complex involved in actine 
reorganization and polimerization. Formation of an actin pedestal is responsible for cell lesions and 
specific symptoms of EPEC infection. Nck is an adaptor with different domains, among which the 
second SH3 domain, Nck-SH3.2, is specifically involved in Tir interaction. Qui et al. [55] have 
reported the design of a synthetic peptide that binds to the Nck-SH3.2 domain at the level of Cys48. 
This interaction blocks the Nck binding site for Tir. Consequently, Tir cannot interact with Arp2/3 
complex and no actin reorganization occurs blocking EPEC infection. The reactive peptide, which 
acts on cells rather than on the pathogen, may be a promising approach to fighting drug resistance. 
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38. Glucuronide Prodrug, PEGylation, Albumin Binder, Self-Immolative Linker, and a Potent 
Toxin: An Ideal Ensemble for Efficient Tumor Suppression Upon Highly Localized Bioactivation 
Highlighted by Jarkko Rautio and Diego Muñoz-Torrero 
Zelikin’s group [56] have reported efficient suppression of tumor growth by enzyme prodrug 
therapy, which takes advantage of noncovalent albumin binding and, subsequently, delivery of the 
prodrug to the tumor as well as the endogenous enzymatic repertoire of the tumor. To this end, a 
total of eight glucuronide prodrugs of highly cytotoxic monomethyl auristatin E (MMAE) were 
engineered, where a self-immolative scaffold based on o-substituted p-hydroxybenzyl alcohol 
provided a spacer between the drug, glucuronide, and either the molecular (e.g., alkyne), 
macromolecular (e.g., PEGs), or supramolecular (e.g., trityl (Tr)-PEG) protraction arm. While most 
prodrugs significantly masked the toxicity of MMAE and were well tolerated after subcutaneous 
administration to an MDA-MB-231 ectopic xenograft mouse model, only the Tr-PEG glucuronide 
prodrug (Figure 12) afforded statistically significant suppression of tumor growth. The best prodrug 
could not be predicted from the in-vitro toxicity screens or in-vivo derived pharmacokinetics 
parameters, but favorable anticancer effects correlated only with accumulation of the released 
payload from the prodrug at the tumor site. This is a very useful approach for all modalities of cancer 
detection, imaging, and treatment relying on enhanced tumor localization! 
 
Figure 12. Chemical structure and mechanism of the bioactivation of the Tr-PEG glucuronide 
supramolecular MMAE prodrug. 
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